[AI Corner, Chat GPT]
See also: Blog on HR 8500, LCD Reform, here
Cosponsor: Barragan (D-CA), Tenney (R-NY)
See also: Blog on HR 8890, CLIA Reform, here
Cosponsor: N.A. (6/12/2026)
##
HEADER
Retiring Florida Congressman Neal Dunn, M.D., has introduced two surprisingly substantive diagnostics bills: H.R. 8500 to discipline Medicare LCD timing and transparency, and H.R. 8890 to modernize CLIA as the home for LDT oversight. Though unlikely to pass standalone, both may become marker bills for future diagnostics policy.
##
Neal Dunn’s Late-Term Diagnostics Bills: A Retiring Physician-Member Takes Aim at LCDs and CLIA
One of the more interesting small dramas in 2026 Medicare diagnostics policy is that two substantial bills on highly technical laboratory and coverage issues are being introduced by a member of Congress who is, in political terms, almost out the door. Congressman Neal Dunn, M.D., a Republican from Florida’s 2nd Congressional District, is a urologist, former Army surgeon, and five-term member of the House. In January 2026, he announced that he would not seek re-election. Yet in the spring of 2026, with only months left in his congressional tenure, Dunn introduced two bills that go directly to the machinery of Medicare coverage and clinical laboratory oversight: H.R. 8500, the Ensuring Timely Access to Coverage Decisions Act, and H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access Act, or Enhancing CLIA Act.
That is the first surprise. These are not symbolic resolutions about apple pie or naming a post office. They are technically meaningful bills in two areas where diagnostics policy has been stuck for years: Medicare local coverage determinations and the status of laboratory-developed tests under CLIA.
H.R. 8500 addresses the Medicare local coverage determination process. LCDs are the decisions by which Medicare Administrative Contractors decide whether particular services are reasonable and necessary in their jurisdictions. For laboratories, device firms, and specialty medicine, LCDs can be enormously consequential. They may determine whether a new test, procedure, or technology receives practical Medicare access, even without a national coverage determination from CMS. But the LCD process has long been criticized as slow, uneven, opaque, and variable across contractors.
Dunn’s H.R. 8500 is framed as a timeliness and transparency bill. It would require more structured handling of LCD requests, more timely completion of requests, more stakeholder involvement, and a formal review process for reconsideration decisions. In simple terms, it tries to make the LCD pathway less of a black box. The bill does not appear to be a grand rewrite of Medicare coverage law. Rather, it focuses on process: when a request is complete, when a contractor must act, how stakeholders are heard, and how reconsideration is handled.
For the diagnostics industry, this matters because LCDs are often where theoretical innovation meets operational Medicare reality. A test may have publications, expert enthusiasm, CPT coding, and even some commercial coverage, but Medicare access often depends on whether a MAC writes or revises an LCD. When that process is slow or indefinite, companies face reimbursement limbo. The policy intuition behind H.R. 8500 is that beneficiaries and innovators should not have to wait indefinitely for an answer, even if the answer is ultimately no.
H.R. 8890 is potentially broader and more politically charged. The Enhancing CLIA Act would update CLIA for modern laboratory-developed testing services. It would reaffirm that LDTs are professional services regulated by CMS under CLIA, not medical devices regulated by FDA. It would also create a public CMS database with key information about LDT performance specifications and validation information; clarify that LDTs include modern analyses of digital laboratory information, such as genomic data derived from previously sequenced patient samples; allow voluntary confirmation by recognized third parties that an LDT is analytically and clinically valid; and establish centralized error reporting with enhanced CMS oversight authority when credible information indicates problems with analytical or clinical validity.
That is the second surprise. The bill is not simply an anti-FDA LDT bill, nor merely an industry deregulatory marker. It tries to do two things at once: preserve the CLIA/CMS framework as the center of gravity for LDT oversight, while adding transparency, validation visibility, error reporting, and clearer accountability. That makes it a kind of “enhanced CLIA” approach—an alternative to FDA device-style regulation, but not a defense of the status quo in its purest form.
The timing is important. The FDA’s attempted LDT rule had already triggered intense opposition from laboratories and trade associations, and the broader legal and policy question was whether LDTs should be treated primarily as medical devices or as clinical laboratory services. Dunn’s bill stakes out the latter view. It says, in effect, that the path forward is not to migrate LDTs into FDA device regulation, but to modernize CLIA so that CMS can supervise laboratory testing in a way that better reflects genomics, digital information, complex algorithms, and modern precision medicine.
The fact that Dunn is a physician matters. A urologist and former Army surgeon from North Florida is not the stereotypical sponsor one might imagine for molecular diagnostics and CLIA modernization. But that may actually be part of the appeal. He can speak as a clinician rather than as a pure industry proxy. His district is not Boston, San Francisco, Cambridge, or Silicon Valley. It is North Florida—Panama City, Tallahassee, and surrounding areas. That gives the bills a different political flavor: access to diagnostic innovation is framed not only as a biotech issue, but as a patient-care and physician-practice issue.
The third surprise is the late-term sponsorship. Because Dunn is retiring, the natural question is whether these bills are meant to pass, or whether they are marker bills. The realistic answer is probably “marker bills, unless something changes.” Standalone Medicare process reform and CLIA modernization are not easy lifts in a crowded election-year Congress. H.R. 8500 has bipartisan elements and could plausibly attract broader support because timeliness and transparency in Medicare coverage are difficult to oppose in principle. H.R. 8890, by contrast, sits closer to the LDT regulation wars and therefore has a more obvious coalition and opposition structure.
Still, marker bills matter. They define language, create a policy baseline, organize stakeholders, and give future sponsors something concrete to inherit. They can be folded into larger Medicare, FDA, appropriations, or health-extender packages. They can also become the template for the next Congress, especially if ACLA, CAP, AMP, AdvaMed, specialty societies, and patient-access groups decide the language is worth defending and refining.
The combined Dunn bills are therefore best understood as a late-term policy intervention by a clinically credentialed member with little time left but significant issue credibility. H.R. 8500 says Medicare contractors should not be allowed to leave coverage requests in indefinite limbo. H.R. 8890 says LDT oversight should be modernized inside CLIA, not transferred wholesale into FDA device regulation. Together, they reflect a surprisingly coherent diagnostics-policy agenda: faster Medicare coverage processes, clearer laboratory oversight, more transparency, and a regulatory architecture that treats advanced diagnostics as clinical services rather than ordinary widgets.
Whether they pass is uncertain. Whether they are important is less uncertain. In Washington, a bill introduced by a retiring member can look like a farewell gesture. In this case, it may be more like a draft blueprint left on the table for the next round of the diagnostics wars.
______________
Key factual anchors: Dunn’s H.R. 8500 press release says the bill targets Medicare LCD delays, inconsistent standards, lack of transparency, stakeholder involvement, timely completion, and a formal reconsideration-review process. (Neal Dunn) Dunn’s H.R. 8890 press release says the Enhancing CLIA Act would update CLIA, reaffirm LDTs as CMS/CLIA-regulated professional services, create a public LDT database, include genomic/digital lab information, support voluntary third-party validity confirmation, and establish error reporting and CMS oversight authority. (Neal Dunn) ACLA publicly welcomed the CLIA bill as preserving CMS as regulator of clinical laboratories while enhancing LDT oversight and transparency. (acla.com)
Source note: Dunn announced on January 13, 2026 that he would not seek re-election after five terms; H.R. 8500 was introduced on April 27/28, 2026 with Reps. Barragán and Tenney; H.R. 8890 was introduced in May 2026 and referred to Energy & Commerce and Ways & Means. (Neal Dunn)
